Saltar al contenido
Merck
Todas las fotos(1)

Documentos

1357056

USP

Leflunomide Related Compound B

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C12H9F3N2O2
Número de CAS:
108605-62-5
Peso molecular:
270.21
Número MDL:
MFCD00910058
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750239
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

leflunomide

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1

InChI

1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-

Clave InChI

UTNUDOFZCWSZMS-YFHOEESVSA-N

Información sobre el gen

human ... DHODH(1723)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Leflunomide Related Compound B (2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide is a malononitrilamide which is a water soluble metabolite of Leflunomide. It is considered as a noncompetitive inhibitor of dihydro-orotate dehydrogensae. This metabolite has been reported to initially target activated lymphocytes.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000654

Leflunomide, European Pharmacopoeia (EP) Reference Standard

Y0000674

Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard

1356960

Leflunomide, United States Pharmacopeia (USP) Reference Standard

Y0000487

Leflunomide impurity A, European Pharmacopoeia (EP) Reference Standard

1357045

Leflunomide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1357067

Leflunomide Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1378

Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1568

Leflunomide Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1233

Leflunomide, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Titia E Vrenken et al.
Journal of hepatology, 49(5), 799-809 (2008-09-24)
Leflunomide is used in the treatment of autoimmune diseases as an anti-inflammatory agent. Leflunomide and its active metabolite A77 1726 modulate mitogen-activated protein kinases (MAPK), Src kinases, the phosphoinositide-3 kinase (PI3K)/Akt-pathway and nuclear factor (NF)-kappaB activation. Both cell protective and
Eva Bernhoff et al.
Journal of virology, 84(4), 2150-2156 (2009-12-04)
The immunomodulatory drug leflunomide is frequently used for treating polyomavirus-associated nephropathy, yet its antiviral mechanism is unclear. We characterized the effects of the active leflunomide metabolite A771726 (LEF-A) on the polyomavirus BK (BKV) life cycle in human renal tubular epithelial
Takeo Sato et al.
Rheumatology (Oxford, England), 48(10), 1265-1268 (2009-08-05)
To elucidate the factors associated with poor prognosis of LEF-induced lung injury in patients with RA. The background and clinical and laboratory features of LEF-induced lung injury were examined and compared between patients who died of and who recovered from
Paola Montagna et al.
Annals of the New York Academy of Sciences, 1193, 30-35 (2010-04-20)
Rheumatoid arthritis (RA) prevalence is greater in females than in males, supporting estrogens as modulators of immune response. Leflunomide (LEF) is employed in the RA treatment. We studied the combinatory effects of LEF active metabolite A77 1726 (LEF-M) and 17beta-estradiol
Li-Xia Xiong et al.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 25(1), 16-19 (2009-01-08)
To observe the inhibitory effects of tyrosine kinases inhibitor A77 1726 on collagen generation induced by IL-13 in fibroblasts. The inhibition rate of fibroblast proliferation with different concentration of A77 1726 was observed by MTT method. The fibroblasts were divided
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico